BRCA1 loss activates cathepsin L-mediated degradation of 53BP1 in breast cancer cells

Journal of Cell Biology

Volumn 200, Issue 2, 2013, Pages 187-202

  Grotsky, David A ^a,b   Gonzalez Suarez, Ignacio ^b   Novell, Anna ^c   Neumann, Martin A ^a,b   Yaddanapudi, Sree C ^b   Croke, Monica ^a   Martinez Alonso, Montserrat ^c   Redwood, Abena B ^b   Ortega Martinez, Sylvia ^b   Feng, Zhihui ^b,d   Lerma, Enrique ^e   Cajal, Teresa Ramon ^e   Zhang, Junran ^b,d   Matias Guiu, Xavier ^c   Dusso, Adriana ^b,c   Gonzalo, Susana ^a,b  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c HOSPITAL UNIVERSITARI ARNAU DE VILANOVA   (Spain)

^d CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; CATHEPSIN L; DNA; DNA REPAIR FACTOR 53BP1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; TUMOR MARKER; UNCLASSIFIED DRUG; VITAMIN D; VITAMIN D RECEPTOR;

ARTICLE; CANCER DIAGNOSIS; CANCER THERAPY; CELL CYCLE ARREST; CELL PROLIFERATION; GENOMIC INSTABILITY; HUMAN; HUMAN CELL; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROTEIN DEGRADATION; RECOMBINATION REPAIR; TRIPLE NEGATIVE BREAST CANCER;

BRCA1 PROTEIN; BREAST NEOPLASMS; CATHEPSIN L; CELL LINE, TUMOR; DNA REPAIR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOMIC INSTABILITY; GERM-LINE MUTATION; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS;

EID: 84873050707     PISSN: 00219525     EISSN: 15408140     Source Type: Journal    
DOI: 10.1083/jcb.201204053     Document Type: Article

References (58)

1. Alvarez-Díaz, S., N. Valle, J.M. García, C. Peña, J.M. Freije, V. Quesada, A. Astudillo, F. Bonilla, C. López-Otín, and A. Muñoz. 2009. Cystatin D is a candidate tumor suppressor gene induced by vitamin D in human colon cancer cells. J. Clin. Invest. 119:2343-2358. http://dx.doi.org/ 10.1172/JCI37205
2. Aly, A., and S. Ganesan. 2011. BRCA1, PARP, and 53BP1: conditional synthetic lethality and synthetic viability. J. Mol. Cell Biol. 3:66-74. http://dx.doi .org/10.1093/jmcb/mjq055
3. Bhattacharyya, A., U.S. Ear, B.H. Koller, R.R. Weichselbaum, and D.K. Bishop. 2000. The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin. J. Biol. Chem. 275:23899-23903. http://dx.doi.org/10.1074/jbc.C000276200
4. Blagosklonny, M.V., W.G. An, G. Melillo, P. Nguyen, J.B. Trepel, and L.M. Neckers. 1999. Regulation of BRCA1 by protein degradation. Oncogene. 18:6460-6468. http://dx.doi.org/10.1038/sj.onc.1203068
5. Bochar, D.A., L. Wang, H. Beniya, A. Kinev, Y. Xue, W.S. Lane, W. Wang, F. Kashanchi, and R. Shiekhattar. 2000. BRCA1 is associated with a human SWI/SNF-related complex: linking chromatin remodeling to breast cancer. Cell. 102:257-265. http://dx.doi.org/10.1016/S0092-8674(00)00030-1
6. Bothmer, A., D.F. Robbiani, N. Feldhahn, A. Gazumyan, A. Nussenzweig, and M.C. Nussenzweig. 2010. 53BP1 regulates DNA resection and the choice between classical and alternative end joining during class switch recombination. J. Exp. Med. 207:855-865. http://dx.doi.org/10 .1084/jem.20100244
7. Bouwman, P., A. Aly, J.M. Escandell, M. Pieterse, J. Bartkova, H. van der Gulden, S. Hiddingh, M. Thanasoula, A. Kulkarni, Q. Yang, et al. 2010. 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers. Nat. Struct. Mol. Biol. 17:688-695. http://dx.doi.org/10.1038/nsmb.1831
8. Bryant, H.E., N. Schultz, H.D. Thomas, K.M. Parker, D. Flower, E. Lopez, S. Kyle, M. Meuth, N.J. Curtin, and T. Helleday. 2005. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 434:913-917. http://dx.doi.org/10.1038/nature03443
9. Bunting, S.F., E. Callén, N. Wong, H.T. Chen, F. Polato, A. Gunn, A. Bothmer, N. Feldhahn, O. Fernandez-Capetillo, L. Cao, et al. 2010. 53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks. Cell. 141:243-254. http://dx.doi.org/ 10.1016/j.cell.2010.03.012
10. Cao, L., S. Kim, C. Xiao, R.H. Wang, X. Coumoul, X. Wang, W.M. Li, X.L. Xu, J.A. De Soto, H. Takai, et al. 2006. ATM-Chk2-p53 activation prevents tumorigenesis at an expense of organ homeostasis upon Brca1 deficiency. EMBO J. 25:2167-2177. http://dx.doi.org/10.1038/sj.emboj.7601115
11. Cao, L., X. Xu, S.F. Bunting, J. Liu, R.H. Wang, L.L. Cao, J.J. Wu, T.N. Peng, J. Chen, A. Nussenzweig, et al. 2009. A selective requirement for 53BP1 in the biological response to genomic instability induced by Brca1 deficiency. Mol. Cell. 35:534-541. http://dx.doi.org/10.1016/ j.molcel.2009.06.037
12. Deng, C., E. Ueda, K.E. Chen, C. Bula, A.W. Norman, R.A. Luben, and A.M. Walker. 2009. Prolactin blocks nuclear translocation of VDR by regulating its interaction with BRCA1 in osteosarcoma cells. Mol. Endocrinol. 23:226-236. http://dx.doi.org/10.1210/me.2008-0075
13. Drew, Y., E.A. Mulligan, W.T. Vong, H.D. Thomas, S. Kahn, S. Kyle, A. Mukhopadhyay, G. Los, Z. Hostomsky, E.R. Plummer, et al. 2011. Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2. J. Natl. Cancer Inst. 103:334-346. http://dx.doi.org/10.1093/jnci/djq509
14. Duncan, E.M., T.L. Muratore-Schroeder, R.G. Cook, B.A. Garcia, J. Shabanowitz, D.F. Hunt, and C.D. Allis. 2008. Cathepsin L proteolytically processes histone H3 during mouse embryonic stem cell differentiation. Cell. 135:284-294. http://dx.doi.org/10.1016/j.cell.2008.09.055
15. Dusso, A.S., A.J. Brown, and E. Slatopolsky. 2005. Vitamin D. Am. J. Physiol. Renal Physiol. 289:F8-F28. http://dx.doi.org/10.1152/ajprenal .00336.2004
16. Evers, B., and J. Jonkers. 2006. Mouse models of BRCA1 and BRCA2 deficiency: past lessons, current understanding and future prospects. Oncogene. 25:5885-5897. http://dx.doi.org/10.1038/sj.onc.1209871
17. Farmer, H., N. McCabe, C.J. Lord, A.N. Tutt, D.A. Johnson, T.B. Richardson, M. Santarosa, K.J. Dillon, I. Hickson, C. Knights, et al. 2005. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 434:917-921. http://dx.doi.org/10.1038/nature03445
18. Fernandez-Capetillo, O., H.T. Chen, A. Celeste, I. Ward, P.J. Romanienko, J.C. Morales, K. Naka, Z. Xia, R.D. Camerini-Otero, N. Motoyama, et al. 2002. DNA damage-induced G2-M checkpoint activation by histone H2AX and 53BP1. Nat. Cell Biol. 4:993-997. http://dx.doi.org/ 10.1038/ncb884
19. Fong, P.C., D.S. Boss, T.A. Yap, A. Tutt, P. Wu, M. Mergui-Roelvink, P. Mortimer, H. Swaisland, A. Lau, M.J. O'Connor, et al. 2009. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 361:123-134. http://dx.doi.org/ 10.1056/NEJMoa0900212
20. Foulkes, W.D., I.E. Smith, and J.S. Reis-Filho. 2010. Triple-negative breast cancer. N. Engl. J. Med. 363:1938-1948. http://dx.doi.org/10.1056/ NEJMra1001389
21. Gartner, E.M., A.M. Burger, and P.M. Lorusso. 2010. Poly(adp-ribose) polymerase inhibitors: a novel drug class with a promising future. Cancer J. 16:83-90. http://dx.doi.org/10.1097/PPO.0b013e3181d78223
22. Gocheva, V., and J.A. Joyce. 2007. Cysteine cathepsins and the cutting edge of cancer invasion. Cell Cycle. 6:60-64. http://dx.doi.org/10.4161/cc .6.1.3669
23. Gonzalez-Suarez, I., A.B. Redwood, and S. Gonzalo. 2009. Loss of A-type lamins and genomic instability. Cell Cycle. 8:3860-3865. http://dx.doi .org/10.4161/cc.8.23.10092
24. Gonzalez-Suarez, I., A.B. Redwood, D.A. Grotsky, M.A. Neumann, E.H. Cheng, C.L. Stewart, A. Dusso, and S. Gonzalo. 2011. A new pathway that regulates 53BP1 stability implicates cathepsin L and vitamin D in DNA repair. EMBO J. 30:3383-3396. http://dx.doi.org/10 .1038/emboj.2011.225
25. Goulet, B., A. Baruch, N.S. Moon, M. Poirier, L.L. Sansregret, A. Erickson, M. Bogyo, and A. Nepveu. 2004. A cathepsin L isoform that is devoid of a signal peptide localizes to the nucleus in S phase and processes the CDP/Cux transcription factor. Mol. Cell. 14:207-219. http://dx.doi .org/10.1016/S1097-2765(04)00209-6
26. Helleday, T., H.E. Bryant, and N. Schultz. 2005. Poly(ADP-ribose) polymerase (PARP-1) in homologous recombination and as a target for cancer therapy. Cell Cycle. 4:1176-1178. http://dx.doi.org/10.4161/ cc.4.9.2031
27. Iliakis, G., H. Wang, A.R. Perrault, W. Boecker, B. Rosidi, F. Windhofer, W. Wu, J. Guan, G. Terzoudi, and G. Pantelias. 2004. Mechanisms of DNA double strand break repair and chromosome aberration formation. Cytogenet. Genome Res. 104:14-20. http://dx.doi.org/10.1159/000077461
28. Jedeszko, C., and B.F. Sloane. 2004. Cysteine cathepsins in human cancer. Biol. Chem. 385:1017-1027. http://dx.doi.org/10.1515/BC.2004.132
29. Kawai, S., and A. Amano. 2012. BRCA1 regulates microRNA biogenesis via the DROSHA microprocessor complex. J. Cell Biol. 197:201-208. http://dx.doi.org/10.1083/jcb.201110008
30. Lankelma, J.M., D.M. Voorend, T. Barwari, J. Koetsveld, A.H. Van der Spek, A.P. De Porto, G. Van Rooijen, and C.J. Van Noorden. 2010. Cathepsin L, target in cancer treatment? Life Sci. 86:225-233. http://dx.doi.org/ 10.1016/j.lfs.2009.11.016
31. Moynahan, M.E., J.W. Chiu, B.H. Koller, and M. Jasin. 1999. Brca1 controls homology-directed DNA repair. Mol. Cell. 4:511-518. http://dx.doi .org/10.1016/S1097-2765(00)80202-6
32. Mullan, P.B., J.E. Quinn, and D.P. Harkin. 2006. The role of BRCA1 in transcriptional regulation and cell cycle control. Oncogene. 25:5854-5863. http://dx.doi.org/10.1038/sj.onc.1209872
33. Neuhausen, S.L., and C.J. Marshall. 1994. Loss of heterozygosity in familial tumors from three BRCA1-linked kindreds. Cancer Res. 54:6069-6072.
34. Olive, P.L., J.P. Banáth, and R.E. Durand. 1990. Heterogeneity in radiationinduced DNA damage and repair in tumor and normal cells measured using the "comet" assay. Radiat. Res. 122:86-94. http://dx.doi.org/10.2307/3577587
35. Pallares, J., M. Santacana, S. Puente, S. Lopez, A. Yeramian, N. Eritja, A. Sorolla, D. Llobet, X. Dolcet, and X. Matias-Guiu. 2009. A reviewof the applications of tissue microarray technology in understanding the molecular features of endometrial carcinoma. Anal. Quant. Cytol. Histol. 31:217-226.
36. Peppone, L.J., A.J. Huston, M.E. Reid, R.N. Rosier, Y. Zakharia, D.L. Trump, K.M. Mustian, M.C. Janelsins, J.Q. Purnell, and G.R. Morrow. 2011. The effect of various vitamin D supplementation regimens in breast cancer patients. Breast Cancer Res. Treat. 127:171-177. http://dx.doi .org/10.1007/s10549-011-1415-4
37. Redwood, A.B., I. Gonzalez-Suarez, and S. Gonzalo. 2011a. Regulating the levels of key factors in cell cycle and DNA repair: new pathways revealed by lamins. Cell Cycle. 10:3652-3657.
38. Redwood, A.B., S.M. Perkins, R.P. Vanderwaal, Z. Feng, K.J. Biehl, I. Gonzalez-Suarez, L. Morgado-Palacin, W. Shi, J. Sage, J.L. Roti-Roti, et al. 2011b. A dual role for A-type lamins in DNA double-strand break repair. Cell Cycle. 10:2549-2560. http://dx.doi.org/10.4161/ cc.10.15.16531
39. Schlegel, B.P., F.M. Jodelka, and R. Nunez. 2006. BRCA1 promotes induction of ssDNA by ionizing radiation. Cancer Res. 66:5181-5189. http://dx.doi .org/10.1158/0008-5472.CAN-05-3209
40. Schultz, L.B., N.H. Chehab, A. Malikzay, and T.D. Halazonetis. 2000. p53 binding protein 1 (53BP1) is an early participant in the cellular response to DNA double-strand breaks. J. Cell Biol. 151:1381-1390. http://dx.doi .org/10.1083/jcb.151.7.1381
41. Scully, R., and D.M. Livingston. 2000. In search of the tumour-suppressor functions of BRCA1 and BRCA2. Nature. 408:429-432. http://dx.doi .org/10.1038/35044000
42. Scully, R., J. Chen, R.L. Ochs, K. Keegan, M. Hoekstra, J. Feunteun, and D.M. Livingston. 1997a. Dynamic changes of BRCA1 subnuclear location and phosphorylation state are initiated by DNA damage. Cell. 90:425-435. http://dx.doi.org/10.1016/S0092-8674(00)80503-6
43. Scully, R., J. Chen, A. Plug, Y. Xiao, D. Weaver, J. Feunteun, T. Ashley, and D.M. Livingston. 1997b. Association of BRCA1 with Rad51 in mitotic and meiotic cells. Cell. 88:265-275. http://dx.doi.org/10.1016/S0092-8674(00)81847-4
44. Sherley, J.L., P.B. Stadler, and J.S. Stadler. 1995. A quantitative method for the analysis of mammalian cell proliferation in culture in terms of dividing and non-dividing cells. Cell Prolif. 28:137-144.
45. Shukla, V., X. Coumoul, T. Lahusen, R.H. Wang, X. Xu, A. Vassilopoulos, C. Xiao, M.H. Lee, Y.G. Man, M. Ouchi, et al. 2010. BRCA1 affects global DNA methylation through regulation of DNMT1. Cell Res. 20:1201-1215. http://dx.doi.org/10.1038/cr.2010.128
46. Skrzydlewska, E., M. Sulkowska, M. Koda, and S. Sulkowski. 2005. Proteolyticantiproteolytic balance and its regulation in carcinogenesis. World J. Gastroenterol. 11:1251-1266.
47. Snouwaert, J.N., L.C. Gowen, A.M. Latour, A.R. Mohn, A. Xiao, L. DiBiase, and B.H. Koller. 1999. BRCA1 deficient embryonic stem cells display a decreased homologous recombination frequency and an increased frequency of non-homologous recombination that is corrected by expression of a brca1 transgene. Oncogene. 18:7900-7907. http://dx.doi .org/10.1038/sj.onc.1203334
48. Sung, P., L. Krejci, S. Van Komen, and M.G. Sehorn. 2003. Rad51 recombinase and recombination mediators. J. Biol. Chem. 278:42729-42732. http://dx .doi.org/10.1074/jbc.R300027200
49. Tanic, M., M. Zajac, G. Gómez-López, J. Benítez, and B. Martínez-Delgado. 2012. Integration of BRCA1-mediated miRNA and mRNA profiles reveals microRNA regulation of TRAF2 and NF?B pathway. Breast Cancer Res. Treat. 134:41-51. http://dx.doi.org/10.1007/s10549- 011-1905-4
50. Tu, Z., K.M. Aird, B.G. Bitler, J.P. Nicodemus, N. Beeharry, B. Xia, T.J. Yen, and R. Zhang. 2011. Oncogenic RAS regulates BRIP1 expression to induce dissociation of BRCA1 from chromatin, inhibit DNA repair, and promote senescence. Dev. Cell. 21:1077-1091. http://dx.doi .org/10.1016/j.devcel.2011.10.010
51. Turner, N.C., and J.S. Reis-Filho. 2006. Basal-like breast cancer and the BRCA1 phenotype. Oncogene. 25:5846-5853. http://dx.doi.org/10.1038/ sj.onc.1209876
52. Tutt, A., M. Robson, J.E. Garber, S.M. Domchek, M.W. Audeh, J.N. Weitzel, M. Friedlander, B. Arun, N. Loman, R.K. Schmutzler, et al. 2010. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proofof- concept trial. Lancet. 376:235-244. http://dx.doi.org/10.1016/S0140- 6736(10)60892-6
53. Wang, B., S. Matsuoka, P.B. Carpenter, and S.J. Elledge. 2002. 53BP1, a mediator of the DNA damage checkpoint. Science. 298:1435-1438.
54. Ward, I.M., K. Minn, J. van Deursen, and J. Chen. 2003. p53 Binding protein 53BP1 is required for DNA damage responses and tumor suppression in mice. Mol. Cell. Biol. 23:2556-2563. http://dx.doi.org/10 .1128/MCB.23.7.2556-2563.2003
55. Wooster, R., and B.L. Weber. 2003. Breast and ovarian cancer. N. Engl. J. Med. 348:2339-2347. http://dx.doi.org/10.1056/NEJMra012284
56. Xie, A., A. Hartlerode, M. Stucki, S. Odate, N. Puget, A. Kwok, G. Nagaraju, C. Yan, F.W. Alt, J. Chen, et al. 2007. Distinct roles of chromatin-associated proteins MDC1 and 53BP1 in mammalian doublestrand break repair. Mol. Cell. 28:1045-1057. http://dx.doi.org/10 .1016/j.molcel.2007.12.005
57. Xu, B., Kim St, and M.B. Kastan. 2001. Involvement of Brca1 in S-phase and G(2)-phase checkpoints after ionizing irradiation. Mol. Cell. Biol. 21:3445-3450. http://dx.doi.org/10.1128/MCB.21.10.3445-3450.2001
58. Zhu, Q., G.M. Pao, A.M. Huynh, H. Suh, N. Tonnu, P.M. Nederlof, F.H. Gage, and I.M. Verma. 2011. BRCA1 tumour suppression occurs via heterochromatin- mediated silencing. Nature. 477:179-184. http://dx.doi.org/ 10.1038/nature10371